Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema.
Request for Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1292

Market Dynamics

The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary angioedema market growth.

Request for Customisation : https://www.coherentmarketinsights.com/insight/request-customization/1292

Key features of the study:

This report provides in-depth analysis of hereditary angioedema market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global hereditary angioedema market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include CSL Behring, Shire Plc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Adverum Biotechnologies, Attune Pharmaceuticals and Pharming Healthcare, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology upgrade, market expansion, and marketing tactics

The global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Detailed Segmentation:

Global Hereditary Angioedema Market, By Drug Class:

C1 Esterase Inhibitor

Kallikrein Inhibitor

Bradykinin Receptor

Attenuated Androgens

Others

Global Hereditary Angioedema Market, By Route of Administration:

Subcutaneous

Intravenous

Oral

Global Hereditary Angioedema Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

Global Hereditary Angioedema Market, By Geography:

North America

By Drug Class:

C1 Esterase Inhibitor

Kallikrein Inhibitor

Bradykinin Receptor

Attenuated Androgens

Others

By Route of Administration:

Subcutaneous

Intravenous

Oral

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

By Country:

U.S.

Canada

Latin America

By Drug Class:

C1 Esterase Inhibitor

Kallikrein Inhibitor

Bradykinin Receptor

Attenuated Androgens

Others

By Route of Administration:

Subcutaneous

Intravenous

Oral

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

e-Commerce

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]